Biofrontera Inc. (NASDAQ:BFRI) Short Interest Up 66.2% in June

Biofrontera Inc. (NASDAQ:BFRI) was the target of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 25,600 shares, an increase of 66.2% from the May 31st total of 15,400 shares. Approximately 0.8% of the company’s stock are sold short. Based on an average daily volume of 79,500 shares, the days-to-cover ratio is presently 0.3 days.

Biofrontera Price Performance

Shares of NASDAQ BFRI remained flat at $0.90 during midday trading on Friday. 14,571 shares of the stock traded hands, compared to its average volume of 25,736. The company’s 50-day moving average price is $1.22 and its two-hundred day moving average price is $1.54. Biofrontera has a twelve month low of $0.61 and a twelve month high of $12.99. The stock has a market capitalization of $4.57 million, a price-to-earnings ratio of -0.07 and a beta of 0.45.

Biofrontera (NASDAQ:BFRI) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($1.63) by ($0.22). Biofrontera had a negative net margin of 69.44% and a negative return on equity of 1,390.99%. The business had revenue of $7.91 million during the quarter, compared to analysts’ expectations of $11.52 million. As a group, equities analysts forecast that Biofrontera will post -3.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Biofrontera stock. Rosalind Advisors Inc. purchased a new position in Biofrontera Inc. (NASDAQ:BFRI) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 504,261 shares of the company’s stock, valued at approximately $777,000. Biofrontera comprises about 0.7% of Rosalind Advisors Inc.’s portfolio, making the stock its 27th biggest position. Rosalind Advisors Inc. owned approximately 9.91% of Biofrontera as of its most recent SEC filing. Institutional investors own 10.08% of the company’s stock.

About Biofrontera

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.